WO2008054597A3 - Tyrosine phosphorylation sites - Google Patents

Tyrosine phosphorylation sites Download PDF

Info

Publication number
WO2008054597A3
WO2008054597A3 PCT/US2007/021086 US2007021086W WO2008054597A3 WO 2008054597 A3 WO2008054597 A3 WO 2008054597A3 US 2007021086 W US2007021086 W US 2007021086W WO 2008054597 A3 WO2008054597 A3 WO 2008054597A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphorylation sites
tyrosine phosphorylation
peptides
phosphorylation site
novel
Prior art date
Application number
PCT/US2007/021086
Other languages
French (fr)
Other versions
WO2008054597A2 (en
WO2008054597A9 (en
Inventor
Peter Hornbeck
Ailan Guo
Klarisa Rikova
Albrecht Moritz
Erik Spek
Anthony Possemato
Charles Farnsworth
Francesco Boccalatte
Jian Yu
Jeffrey Mitchell
John Rush
Valerie Goss
Ting-Lei Gu
Yu Li
Matthew Stokes
Original Assignee
Cell Signaling Technology Inc
Peter Hornbeck
Ailan Guo
Klarisa Rikova
Albrecht Moritz
Erik Spek
Anthony Possemato
Charles Farnsworth
Francesco Boccalatte
Jian Yu
Jeffrey Mitchell
John Rush
Valerie Goss
Ting-Lei Gu
Yu Li
Matthew Stokes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology Inc, Peter Hornbeck, Ailan Guo, Klarisa Rikova, Albrecht Moritz, Erik Spek, Anthony Possemato, Charles Farnsworth, Francesco Boccalatte, Jian Yu, Jeffrey Mitchell, John Rush, Valerie Goss, Ting-Lei Gu, Yu Li, Matthew Stokes filed Critical Cell Signaling Technology Inc
Priority to US12/311,464 priority Critical patent/US20100120055A1/en
Publication of WO2008054597A2 publication Critical patent/WO2008054597A2/en
Publication of WO2008054597A9 publication Critical patent/WO2008054597A9/en
Publication of WO2008054597A3 publication Critical patent/WO2008054597A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

The invention discloses 318 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.
PCT/US2007/021086 2006-09-28 2007-09-28 Tyrosine phosphorylation sites WO2008054597A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/311,464 US20100120055A1 (en) 2006-09-28 2007-09-28 Tyrosine phosphorylation sites

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84774906P 2006-09-28 2006-09-28
US60/847,749 2006-09-28

Publications (3)

Publication Number Publication Date
WO2008054597A2 WO2008054597A2 (en) 2008-05-08
WO2008054597A9 WO2008054597A9 (en) 2008-07-31
WO2008054597A3 true WO2008054597A3 (en) 2008-10-09

Family

ID=39344828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021086 WO2008054597A2 (en) 2006-09-28 2007-09-28 Tyrosine phosphorylation sites

Country Status (2)

Country Link
US (1) US20100120055A1 (en)
WO (1) WO2008054597A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2145902A3 (en) * 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) * 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
WO2010021822A2 (en) 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
EP2239337A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for the prediction of the response of locally advanced rectal cancer to chemoradiotherapy
US8617836B2 (en) 2009-04-10 2013-12-31 Pamgene B.V. Method for predicting the response of locally advanced rectal cancer to chemoradiotherapy
WO2013016465A1 (en) * 2011-07-25 2013-01-31 The Regents Of The University Of California Target of the phosphoinositide 3-kinase pathway
CA2969659A1 (en) * 2014-12-09 2016-06-16 Sapporo Medical University Tumor antigen peptide
KR20200050374A (en) * 2018-10-30 2020-05-11 익스프레션 패톨로지, 인크. Srm/mrm assays for notch pathway proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2268684T3 (en) * 1992-04-10 2007-03-16 Dana-Farber Cancer Institute, Inc. IMMUNODETECTION OF PHOSPHOPROTEIN SPECIFIC TO THE STATE OF ACTIVATION.
MX2007006640A (en) * 2004-12-03 2007-06-19 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ASSAY AND DRUG DEVELOPMENTAL TECHNOLOGIES, April 2004 (2004-04-01) *
DATABASE MEDLINE [online] RUSELLO S.V.: "Assessing cellular protein phosphorylation: high throughput drug discovery technologies", accession no. STN Database accession no. (2004267513) *
GU ET AL.: "Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia", BLOOD FIRST EDITION PAPER AND SUPPLEMENTAL *
JAING ET AL.: "Effect of Tyrosine Mutation on the Kinase Activity and Transforming Potential of an Oncogenic Human Insulin-like Growth Factor 1 Receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, 1996, pages 160 - 167 *
WALTERS ET AL.: "Activating alleles of JAK3 in acute megakaryoblastic leukemia", CANCER CELL, vol. 10, July 2006 (2006-07-01), pages 65 - 75, XP002563379, DOI: doi:10.1016/j.ccr.2006.06.002 *
WETZEL R. ET AL.: "Evaluation of CML model cell lines and imatinib mesylate response: Determinants of signaling profiles", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 305, 2005, pages 59 - 66, XP005106063 *
ZHANG H. ET AL.: "Phosphoprotein Analysis Using Antibodies Broadly Reactive against Phosphorylated Motifs", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, 2002, pages 39379 - 39387, XP002982665 *

Also Published As

Publication number Publication date
US20100120055A1 (en) 2010-05-13
WO2008054597A2 (en) 2008-05-08
WO2008054597A9 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2008013954A3 (en) Tyrosine phosphorylation sites
WO2008073162A3 (en) Lysine acetylation sites
EP1983002A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
WO2008054597A3 (en) Tyrosine phosphorylation sites
WO2008013934A8 (en) Tyrosine phosphorylation sites
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2006010057A3 (en) Therapeutic peptides
EP1972639A3 (en) Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2007056470A3 (en) Neuropilin antagonists
WO2006132670A3 (en) Auristatins having an aminobenzoic acid unit at the n terminus
EP1983003A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
CR20140465A (en) PROTEINS OF UNION TO INTERLEUQUINA-13
WO2006040129A3 (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
ATE442850T1 (en) KAPPA OPIOID RECEPTOR LIGANDS
WO2005047314A3 (en) Fgf-beta binding and supported peptides
IL197831A (en) Human antibodies that bind cxcr4, compositions comprising the same and uses thereof
WO2005086775A3 (en) Lumen-exposed molecules and methods for targeted delivery
WO2008088583A3 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008121767A3 (en) Stitched polypeptides
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2008089397A3 (en) Adrb2 cancer markers
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
DE60225673D1 (en) KAPPA OPIOID RECEPTOR LIGANDS
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867182

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12311464

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07867182

Country of ref document: EP

Kind code of ref document: A2